Home >> Research Area >>Ubiquitination>>Proteasome>> Oprozomib (ONX-0912)

Oprozomib (ONX-0912)

Proteasome inhibitor CAS# 935888-69-0

Oprozomib (ONX-0912)

Catalog No. BCC1146----Order now to get a substantial discount!

Product Name & Size Price Stock
Oprozomib (ONX-0912): 5mg $115 In Stock
Oprozomib (ONX-0912): 10mg Please Inquire In Stock
Oprozomib (ONX-0912): 20mg Please Inquire Please Inquire
Oprozomib (ONX-0912): 50mg Please Inquire Please Inquire
Oprozomib (ONX-0912): 100mg Please Inquire Please Inquire
Oprozomib (ONX-0912): 200mg Please Inquire Please Inquire
Oprozomib (ONX-0912): 500mg Please Inquire Please Inquire
Oprozomib (ONX-0912): 1000mg Please Inquire Please Inquire
Related Products
  • MLN2238

    Catalog No.:BCC2092
    CAS No.:1072833-77-2
  • Gliotoxin

    Catalog No.:BCN3894
    CAS No.:67-99-2

Quality Control of Oprozomib (ONX-0912)

Number of papers citing our products

Chemical structure

Oprozomib (ONX-0912)

3D structure

Chemical Properties of Oprozomib (ONX-0912)

Cas No. 935888-69-0 SDF Download SDF
PubChem ID 25067547 Appearance Powder
Formula C25H32N4O7S M.Wt 532.61
Type of Compound N/A Storage Desiccate at -20°C
Synonyms ONX-0912,ONX0912,ONX 0912,PR 047,Oprozomib
Solubility DMSO : ≥ 50 mg/mL (93.88 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
SMILES CC1=NC=C(S1)C(=O)NC(COC)C(=O)NC(COC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C
Standard InChIKey SWZXEVABPLUDIO-WSZYKNRRSA-N
Standard InChI InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Oprozomib (ONX-0912)

DescriptionOprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5 and LMP7 with IC50 values of 36 nM and 82 nM, respectively.
Targets20S proteasome β520S proteasome LMP7    
IC5036 nM82 nM    

Protocol

Cell experiment:

Cell lines

The human HNSCC cell lines UMSCC-22A, UMSCC-22B, 1483, UMSCC-1, and Cal33.

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

48 h; IC50 values ranging from 58.9 to185.7 nmol/L in 8 different HNSCC cell lines.

Applications

In trypan blue exclusion assays, ONX 0912 exhibited IC50 values ranging from 58.9 to185.7 nmol/L in 8 different HNSCC cell lines. In the 4 HNSCC cell lines (UMSCC-1, UMSCC-22B, 1483, and UMSCC-1) examined, treatment ONX 0912 resulted in processing of caspase-3 to active subunits and cleavage of the caspase substrate PARP.

Animal experiment:

Animal models

Athymic nude mice

Dosage form

30 mg/kg; Oral taken.

Application

Using nude mice harboring HNSCC xenograft tumors, oral administration of 30 mg/kg ONX 0912 effectively inhibited CT-L activity in normal and HNSCC tumor tissues. Treatments (10 mg/kg and 30 mg/kg) were administered via oral gavage once a day on 2 consecutive days and repeated weekly for 2 weeks. Treatment with 10 mg/kg ONX 0912 did not have a significant effect on tumor growth, relative to treatment with vehicle alone. In contrast, highly significant inhibition of HNSCC tumor growth was seen with 30 mg/kg ONX 0912 (P = 0.003). These results show that consecutive-day treatment with orally administered ONX 0912, using a dose that has previously been shown to be well tolerated, leads to inhibition of HNSCC tumor growth.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Zang Y, Thomas S M, Chan E T, et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy[J]. Clinical Cancer Research, 2012, 18(20): 5639-5649.

Oprozomib (ONX-0912) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Oprozomib (ONX-0912) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Oprozomib (ONX-0912)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.8775 mL 9.3877 mL 18.7755 mL 37.5509 mL 46.9387 mL
5 mM 0.3755 mL 1.8775 mL 3.7551 mL 7.5102 mL 9.3877 mL
10 mM 0.1878 mL 0.9388 mL 1.8775 mL 3.7551 mL 4.6939 mL
50 mM 0.0376 mL 0.1878 mL 0.3755 mL 0.751 mL 0.9388 mL
100 mM 0.0188 mL 0.0939 mL 0.1878 mL 0.3755 mL 0.4694 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Oprozomib (ONX-0912)

ONX-0912 (as known as oprozomib), discovered during a medicinal chemistry effort using tripeptide epoxyketones, is an orally bio-available and potent proteasome inhibitor that inhibits growth and induces apoptosis in bortezomib resistant multiple myeloma (MM) cells. Although ONX-0912, an analog of carfilzomib, is structurally distinct from bortezomib, it possesses the same ability as bortezomib to predominantly inhibit chymotrypsin-like activity of the proteasome. ONX-0912 exhibits significant anti-MM activities to reduce tumor progression and prolong survival in many animal tumor model studies, which are associated with activation of caspase-3, caspase-8, caspase-9, and poly(ADP) ribose polymerase and inhibition of anglogensis and MM cells migration.

Reference

Dharminder Chauhan, Ajita V. Singh, Monette Aujay, Christopher J. Kirk, Madhavi Bandi, Bryan Ciccarelli, Noopur Raje, Paul Richardson, and Kenneth C. Anderson. A novel oraaly active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010; 116(23): 4906-4915

Featured Products
New Products
 

Description

Oprozomib (ONX 0912; PR047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Keywords:

Oprozomib (ONX-0912),935888-69-0,ONX-0912,ONX0912,ONX 0912,PR 047,Oprozomib,Natural Products,Proteasome, buy Oprozomib (ONX-0912) , Oprozomib (ONX-0912) supplier , purchase Oprozomib (ONX-0912) , Oprozomib (ONX-0912) cost , Oprozomib (ONX-0912) manufacturer , order Oprozomib (ONX-0912) , high purity Oprozomib (ONX-0912)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: